Literature DB >> 24216276

Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS.

Ji Dong1, Shuaibing Liu, Hua Zhang, Qianli Hua, Xuegang Zhao, Liyan Miao.   

Abstract

A hydrophilic interaction chromatography-tandem mass spectrometric (HILIC-MS/MS) method was developed for the direct determination of naloxone-3-glucuronide (N3G) in human plasma and urine. After a straightforward sample preparation by protein precipitation, N3G was analyzed directly without the need for hydrolysis. Chromatographic separation was performed on a HILIC column. The mobile phase was composed of acetonitrile-10mmol/L ammonium formate (86:14, v/v), with a flow rate of 0.4mL/min. The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode via positive electrospray ionisation (ESI+) source. The linear calibration range was 0.5 to 200ng/mL in plasma and 10 to 5000ng/mL in urine (r(2)>0.99). The intra- and inter-day precision (relative standard deviation, RSD) values were below 15% and the accuracies (relative error, RE) were -7.1% to 2.8% in plasma and -1.3% to 10.3% in urine at three quality control levels. In human subjects receiving 100mg tilidine and 8mg naloxone, mean AUC0-24 of N3G was 160.93±52.77ng/mLh and mean Cmax was 75.33±25.27ng/mL. In 24-h urine samples, 8.0% of the dose was excreted in the form of N3G in urine. These results demonstrated a new method suitable for in vivo pharmacokinetic studies of N3G.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HILIC–MS/MS; Naloxone-3-glucuronide; Pharmacokinetics

Mesh:

Substances:

Year:  2013        PMID: 24216276     DOI: 10.1016/j.jchromb.2013.09.036

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  A high throughput gold nanoparticles chemiluminescence detection of opioid receptor antagonist naloxone hydrochloride.

Authors:  Nawal A Alarfaj; Maha F El-Tohamy
Journal:  Chem Cent J       Date:  2015-02-11       Impact factor: 4.215

2.  A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.

Authors:  Jingyu Zhu; Man Wang; Yang Yu; Huixin Qi; Kunkun Han; Juan Tang; Zubin Zhang; Yuanying Zeng; Biyin Cao; Chunhua Qiao; Hongjian Zhang; Tingjun Hou; Xinliang Mao
Journal:  Oncotarget       Date:  2015-01-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.